anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects will be randomized 1:1 to receive either high dose IV Vitamin C (12g/day) or placebo, every 6 hourly, until successful extubation (minimum 16 doses, maximum 40 doses). Placebo will be the equivalent volume of dextrose 5% given intravenously. Active drug or placebo will be prepared in a sterile method by designated personnel at each site. Active drug or placebo will be prepared in a 50cc syringe and infusion tubing attached, where both are coloured and UV-protected. The recruitment period is expected to be 24 months. Phone call follow-up will be conducted at day 60 (+7 days) post-randomization to review subjects' activities of daily living. All data will be entered electronically into REDCap.

All randomized subjects will be included in the intention-to-treat analysis (ITT) dataset for primary and secondary efficacy endpoints analyses. Safety analysis will be conducted for all subjects who received at least one dose of study drug. There are no interim analyses planned in this trial. At least one safety review will be conducted at 50% target recruitment.
Intervention: Saline placebo. Patients will receive saline placebo on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation. After resuscitation, patients will be treated with saline placebo for a maximum of 9 days (i.e. 7 days corresponding to the stress-dose hydrocortisone treatment of the experimental arm plus 2 days corresponding to the gradual taper of the stress-dose hydrocortisone treatment of the experimental arm).
All employees at YKHC will be invited to complete an online survey that took approximately 10-15 minutes to complete. All employees will receive information via email, which includes an overview of the project, information regarding privacy and consent, and a link to the survey. Those who wish to do so were able to print a copy of the information for their reference. Employees who wish to participate did so by clicking on the survey link. Those who do not wish to participate could simply delete the email. Participants will be given two weeks to complete the online survey. Individuals who do not respond within the first week, will be sent an automated email reminder. All employees who participate will received a small incentive (approximately $10 in value).
Abiraterone acetate is a steroidal irreversible inhibitor of CYP17 (17α hydroxylase/C17, 20-lyase), blocking 2 important enzymatic activities in the synthesis of testosterone. The goal of this study is to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two chemotherapy regimens, one of which contains docetaxel. All patients involved in the study will be randomized (assigned by chance) into one of two arms and will not know what study drug is being given to them. Study drug randomization allocation will be 2:1 (abiraterone acetate: placebo). The study will be conducted in the United States, Canada, Australia, and the EU. The study will consist of screening, treatment, and follow-up. In this study, patients will receive study treatment (abiraterone acetate or placebo) plus prednisone until progression of clinical disease. Follow-up will continue until patient dies, is lost to follow-up, or withdraws informed consent. After providing written informed consent, patients will have screening procedures completed to determine eligibility. Safety evaluations at the screening procedure will include a physical examination, vital signs, and clinical blood laboratory tests, ECG, radiographs, urine tests, and recording of any adverse events including details of current prostate cancer symptoms. Patients will be asked to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 13 weeks after last study drug administration.

Study medication, abiraterone acetate,is an oral (by mouth) medication to be administered as four (4) 250mg abiraterone acetate tablets or 4 placebo tablets to be taken at least one hour before or two hours after a meal anytime up to 10PM everyday. Prednisone will be administered as 5mg orally twice a day for both groups. Each cycle will be 28 days. Study treatment will continue until disease progression as determined by investigator or when the patient meets criteria for withdrawal from study.
OBJECTIVE: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disorder of the peripheral nerves with an incompletely understood underlying pathophysiology. This investigation focused on defining B and T cell frequencies, T cell functional capacity and innate immune system analysis in patients with CIDP.
METHODS: By using multi-parameter flow cytometry, we examined the phenotype and function of PBMCs in 25 CIDP patients who were relatively clinically stable on treatment who met EFNS/PNS criteria, 21 patients with genetically confirmed hereditary neuropathy and 25 healthy controls. We also evaluated the regulatory T cell (Treg) inhibitory capacity by co-culturing Treg and effector T cells.
RESULTS: Proinflammatory CD4 T cells, especially type 1 helper T cell (Th1) and CD8 T cells in patients with CIDP were found to have an enhanced capacity to produce inflammatory cytokines. There was no difference in frequency of Th17 regulatory cells in CIDP patients versus healthy controls, however, Treg function was impaired in CIDP patients. There was no remarkable difference in innate immune system measures. Within B cell subsets, transitional cell frequency was decreased in CIDP patients.
INTERPRETATION: Patients with CIDP clinically stable on treatment continued to show evidence of a proinflammatory state with impaired Treg function. This potentially implies an inadequate suppression of ongoing inflammation not addressed by standard of care therapies as well as persistent activity of disease while on treatment. Targeting T cells, especially inhibiting Th1 and polyfunctional CD8 T cells or improving Treg cell function could be potential targets for future therapeutic research.
WARNING: Administration of Nitrogen may be hazardous or contraindicated. For use only by or under the supervision of a licensed practitioner who is experienced in the use and administration of Nitrogen and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications and side effects, and the precautions to be taken.   
  
WARNING: CONTAINS REFRIGERATED GAS; MAY CAUSE CRYOGENIC BURNS OR INJURY. MAY DISPLACE OXYGEN AND CAUSE RAPID SUFFOCATION.  
  
Do not handle until all safety precautions have been read and understood. Use and store only outdoors or in a well-ventilated place. Wear cold insulating gloves, face shield, and eye protection. Use a back flow preventive device in the piping. DO NOT change or force fit connections. Close valve after each use and when empty. Always keep container in upright position. Read and follow the Safety Data Sheet (SDS) before use.   
  
FIRST AID: IF INHALED: Remove person to fresh air and keep comfortable for breathing. IF ON SKIN: Thaw frosted parts with lukewarm water. Do not rub affected area. Get immediate medical advice/attention.
Patients randomized to Group 2 will receive low literacy, written materials about HCV screening among baby-boomers in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in baby boomers and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody blood test. Written materials will be developed and validated in Spanish using the Spanish Language Translation Resource. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will place a follow-up call to this potential subject. These follow-up calls will occur in the 2nd - 4th week after mailing invitations; up to three attempts in total will be made to reach the patient to facilitate HCC screening completion.
Adipose tissue provides a valuable cell source for tissue engineering, regenerative medicine, and adipose tissue biology studies. The most widely used adipose-derived stromal/stem cells (ASCs) isolation protocol involves enzymatic digestion with collagenase. However, the yield of the method often proves to be poor if not impossible for collection of sufficient stromal vascular fraction (SVF) for expansion when the sample size is small, for instance when only newborn mice are available for cell culture. Here, we describe an efficient protocol for the isolation and expansion of ASCs using explant culture as an alternative. Briefly, adipose tissue was minced after removing excess liquid. Then, the minced tissue was placed in culture dishes or flasks. The cells will migrate out of tissue and adhere to the culture surface after one or more days.
Landmark-guided spinal anesthesia will be performed, via either midline or paramedian approach. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
Instead of playing Attack of the S. Mutans!, children in the control group attended a 90 minute classroom session about virtual reality applications for relieving pain and for therapy. This content was unrelated to oral health.
The invention discloses a high-activity human pancreatic ribonuclease (hRNase) engineered by protein, belonging to the technical field of bioengineering. The invention discloses a human pancreatic ribonuclease mutant obtained by protein engineering and human pancreatic ribonuclease multimerization and active center optimization. Further, a human pancreatic ribonuclease mutant (hRNase-mult) highly resistant to ribonuclease inhibitors was obtained. The improvement of the cytotoxic activity of the mutant hRNase-mult is 10-500 times compared with that of the hRNase. Therefore, the obtained human pancreatic ribonuclease multimeric mutant has good cytotoxic activity, and lays a foundation for the application of the human pancreatic ribonuclease multimeric mutant in the field of health. The invention belongs to the field of protein engineering, and relates to a human pancreatic ribonuclease mutant with high cytotoxicity and a coding gene thereof.
Competitive immunoassays, which employ idiotypic and antiidiotypic monoclonal antibody reagents, are described. These competitive immunoassays are particularly useful for the detection of low concentrations of analyte for which labeled reference analyte is difficult to obtain in quantity. Antiidiotypic monoclonal antibody reagent serves as a substitute for the labeled reference analyte. The antiidiotypic monoclonal antibody reagent exhibits a congruency of structure with one or more epitopes of the analyte or antigen. The antiidiotypic monoclonal antibody is prepared against an idiotypic monoclonal antibody, which, in turn, was prepared against the antigen or analyte. During the immunoassay, the antiidiotypic monoclonal antibody is allowed to compete with the antigen, whose concentration is being determined, for a limited number of antibody binding sites present on an idiotypic antibody, which was also prepared against the antigen or analyte. The idiotypic antibody may be either monoclonal or polyclonal, depending upon the particular immunoassay. The products of the competitive binding reactions are assessed through the use of a signal-generating label attached to either antibody. By employing standards containing known amounts of analyte, the concentration of analyte in a sample fluid may be determined. Analytes detectable by these competitive immunoassays include antigens or antibodies in aqueous fluids, including body fluids such as serum, urine, and the like. Related applications and modifications are also described.
In this study, the Bee Venom gel was prepared in a gel formula. Patients with chronic pressure ulcers were enrolled randomly into two different groups. Group 1 received a topical application of Bee Venom gel, 3 times per weeks. While group 2 received phonophoresis of Bee Venom gel using low frequency ultrasound, 3 times per week. The treatment lasted for 8 consecutive weeks. The Image J Software is used to measure the wound surface area before and after treatment.
A number of psycho-social skills development workshops will be conducted for newly inducted civil servants, based on the problem management plus intervention. Problem Management Plus is a brief low-intensity, trans-diagnostic psychological intervention that helps with existing psychological problems as well as building resilience against future adversity. It addresses a range of psychological and practical problems that participants identify as relevant to their lives, including common mental health problems (WHO, 2016; Dawson, et al., 2015). The workshops will be integrated into the routine induction sessions for trainee civil servants.
The most commonly performed inguinal surgeries in children include inguinal hernia repair with or without orchidopexy (orchiopexy). Eighty children aged 6 months to 6 yr of ASA physical status I or II, undergoing elective unilateral inguinal herniotomy will be included. In caudal group, patients will receive a mixture of 0.5 mg/ kg ketamine in 1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route after anesthesia and before start of surgery. In topical group, at the end of the procedure, after identification and ligation of the hernial sac, a mixture of 0.5 mg/ kg ketamine in 0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord and upon the ilioinguinal nerve in a fan shaped manner by the surgeon. The primary outcome measure will be the time to first request for analgesia. Secondary outcome measures will include the number of analgesic doses required in the first 24 h postoperative, pain scores, sensory and motor block, agitation scores, parent satisfaction and adverse effects in the first 48h postoperative.
1. A compound of formula 1, wherein R1 represents: hydrogen, hydroxy, a group of formula OR7 wherein R7 is C1-C6 alkyl, C2-C6 alkenyl; R2 represents: hydrogen, hydroxy, diethylamino, piperidino, tetrahydropyridino or morpholino; and either R3, taken alone, represents hydrogen or hydroxy, and R4 and R5, when taken alone, independently represent hydrogen, hydroxy or, taken together with the carbon atom, represent a carbonyl group; or R3 and R4, taken together, represent a group of formula wherein R8 and R9 represent a C1-C6 alkyl and R5 represents hydrogen; R6 represents: hydrogen or a phenyl group, optionally substituted by methyl, methoxy or halogen, and the pharmaceutically acceptable salt thereof. 2. A compound according to claim 1, characterized in that R1 represents: hydrogen, hydroxy or methoxy; R2 represents: hydrogen, hydroxy or morpholino; R3 represents hydroxy; R4, taken alone, represents hydroxy; R5, taken alone, represents hydrogen or R4 and R5 taken together with the carbon atom represent a carbonyl group; R6 represents hydrogen, and the pharmaceutically acceptable salt thereof. 3. A compound according to claim 1, which is 14-(1,2,3,6-tetrahydropyridin-1-yl)daunomycinone, or a pharmaceutically acceptable salt thereof. 4. A process for preparing a compound of formula 1, as defined in claim 1, which process comprises: (a) reacting a compound of formula 2, wherein R1 and R3 are as defined in claim 1 and R2 is hydrogen or hydroxy, with a compound of formula 3, wherein R6 is as defined in claim 1, and (b) converting a compound of formula 1 as defined above into a different compound of formula 1 by appropriate chemical reactions, and/or if desired, converting the resulting compound of formula 1 into a pharmaceutically acceptable salt thereof. 5. A process according to claim 4, wherein in step (a) a compound of formula 2 as defined in claim 4 is reacted with a compound of formula 3 as defined in claim 4 in a proper organic solvent at a temperature ranging from -10 degree C. to room temperature and for a period of from 6 to 48 hours. 6. A pharmaceutical composition which comprises, as active ingredient, a compound of formula 1 as defined in any of claims 1 to 3, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable carrier or diluent. 7. A compound of formula 1 as defined in any of claims 1 to 3, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body. 8. Use of a compound of formula 1 as defined in any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of AL amyloidosis, Alzheimer's disease or Down's syndrome. 9. A method of treating a human or animal suffering from, or susceptible to, an amyloidois disease, which method comprises administering thereto a non-toxic and effective amount of a compound of formula (I), as defined in any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof.
Endothelial dysfunction plays a pivotal role in the pathogenesis of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). Dipeptidyl peptidase IV (DPP-4), a cell surface glycoprotein, has been implicated in endothelial inflammation and barrier dysfunction. In this study, the role of DPP-4 on lipopolysaccharide (LPS)-induced pulmonary microvascular endothelial cells (HPMECs) dysfunction and the underlying mechanism were investigated by siRNA-mediated knockdown of DPP-4. Our results indicated that LPS (1 μg/ml) challenge resulted in either the production and releasing of DPP-4, as well as the secretion of IL-6 and IL-8 in HPMECs. DPP-4 knockdown inhibited chemokine releasing and monolayer hyper-permeability in LPS challenged HPMECs. When cocultured with human polymorphonuclear neutrophils (PMNs), DPP4 knockdown suppressed LPS-induced neutrophil-endothelial adhesion, PMN chemotaxis and trans-endothelial migration. Western blotting showed that DPP-4 knockdown attenuated LPS-induced activation of TLR4/NF-κB pathway. Immunoprecipitation and liquid chromatography-tandem mass spectrometry revealed that DPP-4 mediated LPS-induced endothelial inflammation by interacting with integrin-α5β1. Moreover, exogenous soluble DPP-4 treatment sufficiently activated integrin-α5β1 downstream FAK/AKT/NF-κB signaling, thereafter inducing ICAM-1 upregulation in HPMECs. Collectively, our results suggest that endothelia synthesis and release DPP-4 under the stress of endotoxin, which interact with integrin-α5β1 complex in an autocrine or paracrine manner to exacerbate endothelial inflammation and enhance endothelial cell permeability. Therefore, blocking DDP-4 could be a potential therapeutic strategy to prevent endothelial dysfunction in ALI/ARDS.
Evamist (NDC 54868-6157-0) is supplied as a homogeneous solution of estradiol USP, octisalate USP and alcohol USP. The liquid formulation of Evamist is packaged in a glass vial fitted with a metered-dose pump. The unit is encased in a plastic housing with a conical bell opening that controls the distance, angle, and area of application of the metered-dose spray. Each metered-dose pump contains 8.1 mL and is designed to accurately deliver 75 sprays of 90 mcL after priming. One spray contains 1.53 mg estradiol.

Keep out of reach of children.

Alcohol and alcohol-based liquids are flammable. Avoid fire, flame or smoking until the spray has dried

Store at 25°C (77°F) with excursion permitted to 15° to 30°C (59° to 86°F). Do not freeze.
OBJECTIVE: This study aimed to investigate the clinical characteristics of pediatric-onset dystonia in Japan, addressing the diagnostic challenges arising from symptom variations and etiological diversity.
METHODS: From 2020 to 2022, questionnaires were distributed to 1218 board certified child neurologists (BCCNs) by Japanese Society of Child Neurology. In the primary survey, participants were asked to report the number of patients with pediatric-onset dystonia under their care. Subsequently, the follow-up secondary survey sought additional information on the clinical characteristics of these patients.
RESULTS: The primary survey obtained 550 responses (response rate: 45 %) from BCCNs for their 736 patients with dystonia. The predominant etiologies included inherited cases (with DYT10  <PxMD-PRRT2> being the most prevalent, followed by DYT5 <DYT/PARK-GCH1> and ATP1A3-related neurologic disorders), acquired cases (with perinatal abnormalities being the most common), and idiopathic cases. The secondary survey provided clinical insights into 308 cases from 82 BCCNs. Infancy-onset dystonia presented as persistent and generalized with diverse symptoms, primarily linked to ATP1A3-related neurologic disorders and other genetic disorders resembling acquired dystonia. Conversely, childhood/adolescent-onset dystonia showed paroxysmal, fluctuating courses, predominantly affecting limbs. The most common etiologies were DYT5 <DYT/PARK-GCH1> and DYT10 <PxMD-PRRT2>, leading to therapeutic diagnoses.
CONCLUSION: Pediatric-onset dystonia in Japan was treated by 28 % of BCCNs. The majority of cases were inherited, with high prevalence rates of DYT5 <DYT/PARK-GCH1> and DYT10 <PxMD-PRRT2>. Infancy-onset dystonia exhibits diverse etiologies and symptoms, emphasizing the utility of various examinations, including genetic testing. These findings significantly contribute to our understanding of pediatric-onset dystonia in Japan, although this study has the limitation of questionnaire survey.
The invention provides a preparation process for a soft bag injection and a product. The preparation process is characterized by comprising the following steps of: (1) preparing the injection; (2) performing oxygen-free encapsulation; and (3) sterilizing the product. During the oxygen-free encapsulation, the obtained injection is filtered by a filter and is filled into an inner soft bag, and the soft bag is vacuumed, filled with a nitrogen gas and plugged; an outer plastic bag is arranged outside the inner bag package; and a space between the inner bag and the outer bag is vacuumed and filled with the nitrogen gas and an oxygen inhalant is added into the space. The preparation process has the advantages of simplicity and convenient operation. Under the condition that no auxiliary material, such as an antioxidant and the like, is added, the injection is rarely oxidized and decomposed to form peroxides or the peroxides are not decomposed continuously to produce harmful substances, such as aldehyde, ketone and the like. The soft bag injection product has high stability and can prevent the oxidation or decomposition of oxidizable or decomposable ingredients in the soft bag product so as to reduce the decomposition and the production of the harmful substances.
285,356. Drangsholt, C. Feb. 12, 1927, [Convention date]. Medicinal bath preparations.-Alkali humates, for instance the sodium or lithium salts or mixtures thereof, are used for preparing medicinal baths. Humic acid is obtained from peat by crushing, disintegrating with water and heating to 100‹ C., or by freezing followed by heating. The mass is then extracted with alkali carbonate or hydroxide or with sodium sulphide or acid sulphide. Acid is added to the humate solution so obtained to precipitate humic acid which is extracted with a solvent such as alcohol to obtain a substance consisting mainly of hymatomelanic acid from which alkali salts are prepared. Soluble humates, obtained by the freezing process referred to, may be treated directly with acid to obtain the humic acid. The Specification as open to inspection under Sect. 91 (3) (a) states that the humic acid may be dissolved in alkali hydroxide and used without extraction with alcohol. This subject-matter does not appear in the Specification as accepted.